文献速递免疫规划传染病防控与疫情报告

三种商业疫苗对妊娠小母猪猪细小病毒1型的效力比较

Effects of three commercial vaccines against porcine parvovirus 1 in pregnant gilts.
PubMed 文献 · Vaccine · 2021-06-05

三种疫苗均能防止猪细小病毒病相关临床表现,其中亚单位疫苗诱导更早血清转换且唯一能防止攻毒后病毒血症。

要点

  • 三种商业疫苗均能保护后代免受PPV1相关临床表现。
  • 亚单位疫苗诱导更早血清转换,且唯一防止攻毒后病毒血症。
  • 亚单位疫苗组平均窝产仔数最大且临床健康胎儿比例高。

核心结论

  • 三种受试商业疫苗均能预防妊娠小母猪后代出现猪细小病毒病相关临床表现。
  • PPV1亚单位疫苗诱导更早血清转换,且是唯一能防止攻毒后病毒血症的疫苗。

研究设计与样本

  • 组1接种两剂PPV1亚单位疫苗(ReproCyc® ParvoFLEX),间隔三周。
  • 组2接种两剂PPV1二价疫苗(ERYSENG® PARVO),间隔三周。
  • 组3接种两剂PPV1八价疫苗(Porcilis® Ery + Parvo + Lepto),间隔四周。
  • 组4为未处理攻毒对照组;免疫完成后三周人工授精,妊娠约40天以异源PPV1株攻毒,妊娠约90天采集胎儿评估。

主要发现

  • 攻毒对照组所有胎儿均木乃伊化,验证了攻毒模型。
  • 三种评估疫苗均通过防止猪细小病毒病相关临床表现保护后代。
  • PPV1亚单位疫苗诱导小母猪更早血清转换,且是唯一防止攻毒后病毒血症的疫苗。
  • 该亚单位疫苗组平均窝产仔数最大,平均临床健康胎儿比例高。

临床怎么用

  • 在PPV1防控中,三种商业疫苗均可用于预防妊娠小母猪后代出现相关临床表现。
  • 若需更早血清转换或防止攻毒后病毒血症,可优先考虑PPV1亚单位疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine parvovirosis is a common and important cause of reproductive failure in naïve dams. Even though vaccination is generally effective at preventing disease occurrence, the homology between the vaccine and challenge strains has been recently suggested to play a role in protection. Therefore, the purpose of this study was to evaluate and compare the efficacy of three currently available commercial vaccines against porcine parvovirus genotype 1 (PPV1) in an experimental model using pregnant gilts. Seventy-seven PPV1-negative gilts were included in the trial and randomly allocated to four groups. In group 1, gilts received two doses, three weeks apart, of a PPV1 subunit vaccine (ReproCyc® ParvoFLEX). Following the same scheme, gilts from group 2 received two doses of a PPV1 bivalent vaccine (ERYSENG® PARVO). In group 3, gilts received two doses, four weeks apart, of a PPV1 octavalent vaccine (Porcilis® Ery + Parvo + Lepto). Lastly, gilts from group 4 were left untreated and were used as challenge controls. All gilts were artificially inseminated three weeks after completion of vaccination. Pregnant animals were subsequently challenged around 40 days of gestation with a heterologous PPV1 strain. Foetuses were harvested at around day 90 of gestation and evaluated for their macroscopic appearance (i.e., normal, mummified, or autolytic). Along the study, safety parameters after vaccination, antibody responses against PPV1 and viremia in gilts were also measured. All the foetuses in the challenge control group were mummified, which validated the challenge model, whereas the three evaluated vaccines protected the progeny against PPV1 by preventing the appearance of clinical manifestations associated to parvovirosis. Remarkably, the PPV1 subunit vaccine induced an earlier seroconversion of gilts and was the only vaccine that could prevent viremia after challenge. This vaccine also achieved the largest average litter size accompanied with a high average proportion of clinically healthy foetuses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Noguera M, Vela A, Kraft C, et al. Effects of three commercial vaccines against porcine parvovirus 1 in pregnant gilts. Vaccine. 2021. PMID: 34099327. doi:10.1016/j.vaccine.2021.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。